Overview |
bs-20763R-FITC |
PARP1 Polyclonal Antibody, FITC Conjugated |
WB, FCM |
Human, Mouse, Rat |
Cow, Sheep, Pig, Rabbit |
Specifications |
FITC |
Rabbit |
KLH conjugated synthetic peptide derived from human PARP1 |
581-650/1014 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
6352 |
P09874 |
Nucleus |
RANTES; CCL5; TCP228; Small Inducible Cytokine A5; CCL5; SISd; MGC17164; SCYA5; RANTES; D17S136E; SIS-delta; chemokine (C-C motif) ligand 5; regulated on activation normal T cell expressed and secreted; chemokine (C-C motif) ligand 5; T-cell-specific protein RANTES; C-C motif chemokine 5; EoCP; Eosinophil chemotactic cytokine; RANTES(3-68); RANTES(4-68); CCL5_HUMAN; |
Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |